Unknown

Dataset Information

0

Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.


ABSTRACT: In recent years, a number of drugs have been approved for the treatment of cystic fibrosis (CF). Among them, newly released Trikafta, a combination of 3 drugs (VX-661/VX-445/VX-770), holds great promise to radically improve the quality of life for a large portion of patients with CF carrying 1 copy of F508del, the most frequent CF transmembrane conductance regulator (CFTR) mutation. Currently available disease-modifying CF drugs work by rescuing the function of the mutated CFTR anion channel. Recent research has shown that membrane lipids, and the cell lipidome in general, play a significant role in the mechanism of CFTR-defective trafficking and, on the other hand, its rescue. In this paper, by using untargeted lipidomics on CFBE41o- cells, we identified distinctive changes in the bronchial epithelial cell lipidome associated with treatment with Trikafta and other CF drugs. Particularly interesting was the reduction of levels of ceramide, a known molecular player in the induction of apoptosis, which appeared to be associated with a decrease in the susceptibility of cells to undergo apoptosis. This evidence could account for additional beneficial roles of the triple combination of drugs on CF phenotypes.

SUBMITTER: Liessi N 

PROVIDER: S-EPMC7455125 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.

Liessi Nara N   Pesce Emanuela E   Braccia Clarissa C   Bertozzi Sine Mandrup SM   Giraudo Alessandro A   Bandiera Tiziano T   Pedemonte Nicoletta N   Armirotti Andrea A  

JCI insight 20200820 16


In recent years, a number of drugs have been approved for the treatment of cystic fibrosis (CF). Among them, newly released Trikafta, a combination of 3 drugs (VX-661/VX-445/VX-770), holds great promise to radically improve the quality of life for a large portion of patients with CF carrying 1 copy of F508del, the most frequent CF transmembrane conductance regulator (CFTR) mutation. Currently available disease-modifying CF drugs work by rescuing the function of the mutated CFTR anion channel. Re  ...[more]

Similar Datasets

| S-EPMC2636952 | biostudies-literature
| S-EPMC3929646 | biostudies-literature
2017-05-18 | GSE74365 | GEO
| S-EPMC4566109 | biostudies-literature
| S-EPMC8266292 | biostudies-literature
| S-EPMC8371023 | biostudies-literature
| S-EPMC2424193 | biostudies-literature
| S-EPMC8467635 | biostudies-literature
| S-EPMC8391758 | biostudies-literature
| S-EPMC5427149 | biostudies-literature